Author: Katie Wright

The specialty pharmaceutical company, Aytu BioPharma, announced an update today for the VEDS community on the PREVEnt trial for enzastaurin. The PREVEnt trial is expected to begin in late 2022 or early 2023. This study will be investigating the ability of enzastaurin to reduce the severe complications of VEDS. There are currently no FDA-approved therapies for VEDS.  Aytu BioPharma CEO Josh Disbrow shares the following:  “Dear Vascular Ehlers-Danlos Syndrome Community: Thank…

Read More

Aytu BioPharma, a pharmaceutical company focused on developing and commercializing novel therapeutics, has announced the initiation of the global Phase 3 PREVEnt (Prevention of Ruptures with Enzastaurin for Vascular Ehlers-Danlos Syndrome) clinical trial of enzastaurin (AR101) for the treatment of patients with COL3A1-positive Vascular Ehlers-Danlos Syndrome (VEDS). The company has begun patient identification and study site contracting and has…

Read More

Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, yesterday announced the initiation of patient screening in its Phase 3 DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) clinical trial of EDSIVO™ (celiprolol) for the treatment of patients with COL3A1-positive vascular Ehlers-Danlos Syndrome…

Read More

Registration is now open for the second international patient symposium on genetic aortic and vascular conditions, which is set for Sunday, August 28, 2022, at Le Méridien Etoile in Paris, France. Registration is free, but required. Please register here. Confirmed speakers include: Dr. Juan Bowen, Mayo Clinic, Dr. Alan Braverman, Washington University in St. Louis, Dr. Scott LeMaire, Baylor-St….

Read More

Did you know that free Medical IDs are available to people with Vascular Ehlers-Danlos syndrome (VEDS) through The VEDS Movement? Thanks to a generous donation from the Daskal Family Foundation for the VEDS Emergency Awareness Project, and through a partnership with Sticky J, a medical ID bracelet company, bracelets are now available to people affected by VEDS in the…

Read More

The specialty pharmaceutical company, Aytu BioPharma, announced this week that it anticipates the PREVEnt trial will begin in late 2022 or early 2023. This study will be investigating the ability of enzastaurin to reduce the severe complications of VEDS. There are currently no FDA-approved therapies for VEDS.  Aytu BioPharma CEO Josh Disbrow writes the following:  “Aytu BioPharma remains committed to the conduct of the PREVEnt Clinical Trial testing AR101 (enzastaurin) in VEDS. Through our global Contract…

Read More

Registration is Open for The Marfan Foundation’s E3 Conference, held in Association with Hoag Memorial Hospital Presbyterian, in Newport Beach, CA, July 7-10, 2022 The Marfan Foundation, in association with Hoag Memorial Hospital Presbyterian, will hold its E3 Conference: Educating, Empowering, and Enriching Our Community, in Newport Beach, CA, July 7-10, bringing together more than 600 individuals and families…

Read More

The Marfan Foundation, which has a long history of bringing together the international research community, announced the new date for its second international patient symposium on genetic aortic and vascular conditions. The one-day symposium is now scheduled for Sunday, August 28, 2022, at Le Méridien Etoile in Paris, France. The focus of the meeting is What’s New in Genetic…

Read More

Aytu BioPharma, Inc., a pharmaceutical company focused on developing and commercializing novel therapeutics, announced on March 2, 2022 that the European Commission granted orphan designation to AR101 (enzastaurin), a PKCβ inhibitor, for the treatment of Ehlers-Danlos Syndrome (EDS), a group of rare inherited connective tissue disorders that includes the severe subtype vascular EDS (VEDS). This designation is based on…

Read More